gamma-Aminobutyric acid as a biomarker of the lateralizing and monitoring drug effect in patients with magnetic resonance imaging-negative temporal lobe epilepsy

IntroductionDespite verifying proton magnetic resonance spectroscopy (H-1-MRS) for focal localization in magnetic resonance imaging (MRI)-negative temporal lobe epilepsy (TLE), it is necessary to illustrate metabolic changes and screen for effective biomarkers for monitoring therapeutic effect. We used H-1-MRS to investigate the role of metabolic levels in MRI-negative TLE. Materials and methodsThirty-seven patients (n = 37, 14 women) and 20 healthy controls (n = 20, 11 women) were investigated by H-1-MRS. We compared the metabolite level changes in the epileptic and contralateral sides on the mesial temporal and dorsolateral prefrontal cortices and analyzed their association with clinical symptoms. Results gamma-Aminobutyric acid (GABA) levels were significantly lower on the epileptic side (2.292 +/- 0.890) than in the contralateral side (2.662 +/- 0.742, p = 0.029*) in patients on the mesial temporal lobe. N-acetylaspartate (NAA) levels were significantly lower on the epileptic side (7.284 +/- 1.314) than on the contralateral side (7.655 +/- 1.549, p = 0.034*). NAA + N-acetylaspartylglutamate levels were significantly lower on the epileptic side (7.668 +/- 1.406) than on the contralateral side (8.086 +/- 1.675, p = 0.032*). Glutamate levels were significantly lower on the epileptic side (7.773 +/- 1.428) than on the contralateral side (8.245 +/- 1.616, p = 0.040*). Moreover, a significant negative correlation was found between GABA levels in the epileptic mesial temporal lobe and tonic-clonic seizure frequency (r = -0.338, p = 0.046*). Conclusion gamma-Aminobutyric acid (GABA) is a potential biomarker for lateralization and monitoring seizure frequency in MRI-negative TLE.